Non Hodgkin Lymphoma Clinical Trial
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
Summary
The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.
Eligibility Criteria
Inclusion Criteria:
Pathologically confirmed high-risk recurrent/relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL), after non-response to or failure of first-line standard therapy prior to a definitive therapy e.g.high-dose chemotherapy/autologous stem cell transplant (HDCT/ASCT)
Participants with pathologically confirmed R/R NHL after failure or non-response to second line therapy, including but not limited to primary mediastinal B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), mediastinal gray zone lymphoma (MGZL), anaplastic large cell lymphoma (ALCL), or peripheral T-cell lymphoma (PTCL).
Participants must have measurable PET positive disease in both cHL and NHL cohorts.
Exclusion Criteria:
Aggressive B-cell lymphomas subtypes including Burkitt lymphoma (BL), lymphoblastic lymphoma, and NK/T-cell lymphoma/leukemia.
Primary CNS lymphoma of the brain or spinal cord, and secondary CNS lymphoma (ie, from systemic non-Hodgkin lymphoma) involving the brain, spinal cord, or with leptomeningeal seeding.
Prior treatment with an anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways, with the exception of anti-PD(L)-1 targeted therapies
Prior treatment with lymphocyte activation gene-3 (LAG-3)-targeted agents
Prior autologous stem cell transplantation (HDCT/ASCT)
History of allogeneic bone marrow transplantation.
Other protocol-defined inclusion/exclusion criteria apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 73 Locations for this study
Phoenix Arizona, 85016, United States More Info
Palo Alto California, 94304, United States More Info
New Haven Connecticut, 06510, United States More Info
Contact
Fort Myers Florida, 33908, United States More Info
Contact
West Palm Beach Florida, 33407, United States
Minneapolis Minnesota, 55454, United States More Info
Saint Louis Missouri, 63110, United States More Info
Hackensack New Jersey, 07601, United States More Info
Valhalla New York, 10595, United States More Info
Contact
Hershey Pennsylvania, 17033, United States More Info
Austin Texas, 78723, United States More Info
Madison Wisconsin, 53792, United States
La Tronche , 38700, France More Info
Contact
Marseille , 13385, France
Paris , 75935, France More Info
Rennes , 35203, France
Strasbourg , 67000, France More Info
Contact
Aachen , 52074, Germany
Berlin , 13353, Germany
Giessen , 35392, Germany
Hamburg , 20246, Germany
Muenster , 48149, Germany
Munich , 80337, Germany
Esplugues de Llobregat , 08950, Spain More Info
Contact
Sevilla , 41009, Spain
Nottingham Nottinghamshire, NG5 1, United Kingdom More Info
Contact
Bristol Somerset, BS2 8, United Kingdom
Birmingham West Midlands, B4 6N, United Kingdom
How clear is this clinincal trial information?